At the moment, the focus should be on T2DM since it is perceived as a major risk factor for CVD and patients might benefit from an optimized treatment with renin–angiotensin system antagonists and β-blockers regarding cardiac events or the optimization/introduction of novel therapies. The gene discussed is REN; the disease is type 2 diabetes mellitus.